Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Coronary Syndrome-Pipeline Review, H1 2015

Acute Coronary Syndrome-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Coronary Syndrome-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Coronary Syndrome-Pipeline Review, H1 2015', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Coronary Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Coronary Syndrome Overview 9

Therapeutics Development 10

Pipeline Products for Acute Coronary Syndrome-Overview 10

Pipeline Products for Acute Coronary Syndrome-Comparative Analysis 11

Acute Coronary Syndrome-Therapeutics under Development by Companies 12

Acute Coronary Syndrome-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Acute Coronary Syndrome-Products under Development by Companies 18

Acute Coronary Syndrome-Companies Involved in Therapeutics Development 20

advanceCor GmbH 20

Arena Pharmaceuticals, Inc. 21

Artery Therapeutics, Inc. 22

AstraZeneca PLC 23

Athera Biotechnologies AB 24

Auspex Pharmaceuticals, Inc. 25

Bayer AG 26

Esperion Therapeutics, Inc. 27

GlaxoSmithKline Plc 28

Lee's Pharmaceutical Holdings Limited 29

MedImmune, LLC 30

Pfizer Inc. 31

The Medicines Company 32

Vitae Pharmaceuticals, Inc. 33

XOMA Corporation 34

Acute Coronary Syndrome-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

4-WF-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

AEM-28-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

AEM-28-02-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Artpep-2-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Biologics for Acute Coronary Syndrome-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

bivalirudin-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

cangrelor-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

COR-2-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

COR-3-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

gevokizumab-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

losmapimod-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

MDCO-216-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

MEDI-6012-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MTP-131-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

PC-mAb-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

PF-06282999-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PMC-6-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

PR-15-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

rivaroxaban-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

SD-970-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

temanogrel hydrochloride-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

VTP-38443-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

ZK-001-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Acute Coronary Syndrome-Recent Pipeline Updates 82

Acute Coronary Syndrome-Dormant Projects 108

Acute Coronary Syndrome-Discontinued Products 111

Acute Coronary Syndrome-Product Development Milestones 113

Featured News & Press Releases 113

May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 113

Mar 15, 2015: Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome 113

Oct 22, 2014: NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack 114

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 115

Aug 29, 2014: Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO in Addressing Critical Medical Needs 116

Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 118

Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome 118

Oct 07, 2013: Regulatory Update on Bayer's Xarelto (Rivaroxaban) 2.5 mg in ACS Indication 120

Sep 03, 2013: Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published 120

Jun 28, 2013: FDA Issues Complete Response Letter for XARELTO to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome 121

Appendix 123

Methodology 123

Coverage 123

Secondary Research 123

Primary Research 123

Expert Panel Validation 123

Contact Us 123

Disclaimer 124

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H1 2015 10

Number of Products under Development for Acute Coronary Syndrome-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Acute Coronary Syndrome-Pipeline by advanceCor GmbH, H1 2015 20

Acute Coronary Syndrome-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 21

Acute Coronary Syndrome-Pipeline by Artery Therapeutics, Inc., H1 2015 22

Acute Coronary Syndrome-Pipeline by AstraZeneca PLC, H1 2015 23

Acute Coronary Syndrome-Pipeline by Athera Biotechnologies AB, H1 2015 24

Acute Coronary Syndrome-Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 25

Acute Coronary Syndrome-Pipeline by Bayer AG, H1 2015 26

Acute Coronary Syndrome-Pipeline by Esperion Therapeutics, Inc., H1 2015 27

Acute Coronary Syndrome-Pipeline by GlaxoSmithKline Plc, H1 2015 28

Acute Coronary Syndrome-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 29

Acute Coronary Syndrome-Pipeline by MedImmune, LLC, H1 2015 30

Acute Coronary Syndrome-Pipeline by Pfizer Inc., H1 2015 31

Acute Coronary Syndrome-Pipeline by The Medicines Company, H1 2015 32

Acute Coronary Syndrome-Pipeline by Vitae Pharmaceuticals, Inc., H1 2015 33

Acute Coronary Syndrome-Pipeline by XOMA Corporation, H1 2015 34

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Stage and Target, H1 2015 37

Number of Products by Stage and Mechanism of Action, H1 2015 39

Number of Products by Stage and Route of Administration, H1 2015 41

Number of Products by Stage and Molecule Type, H1 2015 43

Acute Coronary Syndrome Therapeutics-Recent Pipeline Updates, H1 2015 82

Acute Coronary Syndrome-Dormant Projects, H1 2015 108

Acute Coronary Syndrome-Dormant Projects (Contd..1), H1 2015 109

Acute Coronary Syndrome-Dormant Projects (Contd..2), H1 2015 110

Acute Coronary Syndrome-Discontinued Products, H1 2015 111

Acute Coronary Syndrome-Discontinued Products (Contd..1), H1 2015 112

List of Figures

Number of Products under Development for Acute Coronary Syndrome, H1 2015 10

Number of Products under Development for Acute Coronary Syndrome-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Top 10 Targets, H1 2015 36

Number of Products by Stage and Top 10 Targets, H1 2015 36

Number of Products by Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Top 10 Routes of Administration, H1 2015 40

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 41

Number of Products by Top 10 Molecule Types, H1 2015 42

Number of Products by Stage and Top 10 Molecule Types, H1 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

advanceCor GmbH

Arena Pharmaceuticals, Inc.

Artery Therapeutics, Inc.

AstraZeneca PLC

Athera Biotechnologies AB

Auspex Pharmaceuticals, Inc.

Bayer AG

Esperion Therapeutics, Inc.

GlaxoSmithKline Plc

Lee's Pharmaceutical Holdings Limited

MedImmune, LLC

Pfizer Inc.

The Medicines Company

Vitae Pharmaceuticals, Inc.

XOMA Corporation

Acute Coronary Syndrome Therapeutic Products under Development, Key Players in Acute Coronary Syndrome Therapeutics, Acute Coronary Syndrome Pipeline Overview, Acute Coronary Syndrome Pipeline, Acute Coronary Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com